Study on Adherence to Erlotinib in Cancer Patients
Author Information
Author(s): Timmers Lonneke, Boons Christel CLM, Mangnus Dirk, Moes Josee E, Swart Eleonora L, Boven Epie, Smit Egbert F, Hugtenburg Jacqueline G
Primary Institution: VU University Medical Center
Hypothesis
Side-effects play an important role in the way patients use erlotinib.
Conclusion
The study aims to provide insights into patients' experiences with erlotinib and factors affecting adherence.
Supporting Evidence
- Adherence to pharmacological therapy is complex and can significantly affect treatment outcomes.
- Cancer patients have similar adherence rates to those with other diseases.
- Poor adherence can lead to worse health outcomes and higher healthcare costs.
- The study will explore various factors influencing adherence to erlotinib.
Takeaway
This study looks at how well cancer patients stick to their erlotinib medication and what affects their ability to do so.
Methodology
A multicenter, prospective observational cohort study following 65 NSCLC patients for up to 16 weeks, measuring adherence, plasma concentration, and side-effects.
Potential Biases
The Hawthorne effect may influence adherence as patients are aware they are being monitored.
Limitations
The study may be limited by the self-reported nature of adherence and potential biases in patient responses.
Participant Demographics
Patients aged 18 years or older with advanced NSCLC starting treatment with erlotinib.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website